Chongqing Precision Biotech Co., Ltd   Report issue

For profit Phase 1 Phase 2
Founded: Chongqing China (2016)

Organization Overview

First Clinical Trial
2019
NCT04271644
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Chongqing Precision Biotech Co., Ltd | Precision Biotech Taiwan Corp.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, B-Cell (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Pancreatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 33
  • # of Trial APIs: 12